Loading...
OTCM
PGABF
Market cap2mUSD
Mar 31, Last price  
0.36USD
Name

Prostatype Genomics AB

Chart & Performance

D1W1MN
OTCM:PGABF chart
P/E
P/S
624.70
EPS
Div Yield, %
Shrs. gr., 5y
-36.00%
Rev. gr., 5y
21.85%
Revenues
199k
-85.32%
101,5004,995,515161,84374,085683,87810,001682,7981,356,000199,000
Net income
-41m
L-0.93%
-11,490,046-4,746,536-9,318,001-8,545,928-17,408,222-15,629,758-29,086,533-41,435,000-41,051,000
CFO
-45m
L+53.44%
00-5,709,718-9,630,789-14,711,931-16,078,210-27,693,382-29,138,000-44,709,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The test is based on database containing prostate cancer patients and provides decision support for patients and doctors when making a treatment decision. The company was founded in 2007 and is based in Solna, Sweden.
IPO date
Nov 03, 2020
Employees
6
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑062018‑062017‑062016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT